Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT00886990Completed

Efficacy and Safety of Single Versus Double Ritonavir-boosted Protease Inhibitor (PI)-Based Antiretroviral Therapy (ART) Regimens

Role: collaborator

NCT00476424Phase 2Completed

A Pharmacokinetic Study of Once Daily Efavirenz 400 mg Versus 600 mg in Thai HIV-1 Infected Subjects

Role: collaborator

NCT01159275Phase 1Completed

Lopinavir (LPV) Dose Reduction

Role: collaborator

NCT00887120Phase 2Completed

Dose Reduction of Lopinavir in Children

Role: collaborator

NCT01225406Completed

Third Line Highly Active Antiretroviral Therapy (HAART) in HIV-infected Children

Role: collaborator

All 5 trials loaded